<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">6128150</PMID>
      <DateCompleted>
        <Year>1983</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0306-4492</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>72</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>1982</Year>
            </PubDate>
          </JournalIssue>
          <Title>Comparative biochemistry and physiology. C: Comparative pharmacology</Title>
          <ISOAbbreviation>Comp Biochem Physiol C Comp Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neuropharmacology of adrenergic neurons in teleost fish.</ArticleTitle>
        <Pagination>
          <StartPage>289</StartPage>
          <EndPage>302</EndPage>
          <MedlinePgn>289-302</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Although this brief review is based on relatively few types of experiments in few species of teleosts, it is possible to summarize some points of interest regarding the similarities and differences in the mechanisms of adrenergic neurotransmission in fish compared to the higher vertebrates. 1. There is a substantial mixing of cranial autonomic ("parasympathetic") and spinal autonomic ("sympathetic") pathways in the cranial nerves. This close relationship between the two systems and the differences in the nature of the neurons of cranial origin (cholinergic, and non-adrenergic, non-cholinergic) and spinal origin (adrenergic, cholinergic and mixed "polynergic") gives a basis in fish also for a complex pattern of innervation of the various organs. 2. Adrenaline is the major transmitter substance in the adrenergic neurons of most teleosts studied, but there are exceptions within the same species. For instance, in the swimbladder mucosa of the cod, noradrenaline dominates, while adrenaline is the major catecholamine in most other organs innervated by adrenergic neurons. The reasons for the regional differences are not known and further studies of the rate of catecholamine turn-over in the adrenergic neurons of fish are clearly indicated. 3. Adrenoceptors of both the alpha- and the beta-type show great similarities with those of mammals. Some differences in the potencies of certain compounds (e.g., clonidine and methoxamine) exist and receptor binding studies should add valuable information about the adrenoceptors of teleosts. The existence of a subtype of beta-adrenoceptor (beta 2) has been proposed and further work is needed to confirm or deny the applicability of the beta 1/beta 2 adrenoceptor terminology in fish. 4. There appears to be some differences in the mode of action of the so called "indirectly acting amines", such as tyramine, between teleosts and mammals. While the uptake of tyramine into the nerve terminals in mammals appears to take place via the cocaine-sensitive neuronal uptake system which is also responsible for catecholamine uptake (uptake 1), tyramine uptake in cod neurons appears to be via a separate pathway. 5. Presynaptic supersensitivity of the type seen in mammals has also been demonstrated in teleost adrenergic neurons. Both denervation (chemical or surgical) and blockade of the neuronal uptake mechanism by cocaine or desipramine produce this type of supersensitivity, while post-synaptic supersensitivity has so far not been described in teleosts. The effects of removal of the uptake system shows that the uptake process may be as important in teleosts as in mammals in the removal of adrenergic transmitter from the synaptic cleft. 6. In the total picture of adrenergic functions in fish, the circulating catecholamines take a special role...</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Holmgren</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nilsson</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Comp Biochem Physiol C Comp Pharmacol</MedlineTA>
        <NlmUniqueID>7503763</NlmUniqueID>
        <ISSNLinking>0306-4492</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006892">Hydroxydopamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011941">Receptors, Adrenergic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8HW4YBZ748</RegistryNumber>
          <NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I5Y540LHVR</RegistryNumber>
          <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>TG537D343B</RegistryNumber>
          <NameOfSubstance UI="D003891">Desipramine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X8ZC7V0OX3</RegistryNumber>
          <NameOfSubstance UI="D014439">Tyramine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000320" MajorTopicYN="N">Adrenergic Fibers</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003042" MajorTopicYN="N">Cocaine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003891" MajorTopicYN="N">Desipramine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005399" MajorTopicYN="N">Fishes</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006892" MajorTopicYN="N">Hydroxydopamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011941" MajorTopicYN="N">Receptors, Adrenergic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014439" MajorTopicYN="N">Tyramine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>144</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1982</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1982</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1982</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">6128150</ArticleId>
        <ArticleId IdType="doi">10.1016/0306-4492(82)90096-x</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
